Study guide
8.3 Device-Related Safety Reporting & Unanticipated Adverse Device Effects (UADEs)
SOCRA CCRP Certified Clinical Research Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Ethical Codes & Guidelines
1.1 The Nuremberg Code (1947) 1.2 The Declaration of Helsinki (1964) 1.3 The Belmont Report (1979)
2 Chapter 2: U.S. Federal Regulatory Framework
2.1 FDA vs. HHS Governance & 45 CFR Part 46 2.2 Electronic Records & Signatures (21 CFR Part 11) 2.3 Financial Disclosure Requirements (21 CFR Part 54)
3 Chapter 3: Institutional Review Boards & Informed Consent
3.1 IRB Structure, Roles, and Responsibilities (21 CFR Part 56) 3.2 Informed Consent Core Elements & Process (21 CFR Part 50) 3.3 Informed Consent in Special Circumstances & Exceptions 3.4 Vulnerable Populations & Additional Safeguards (Subparts B, C, D)
4 Chapter 4: Protocol & Essential Documentation
4.1 Protocol Design and Investigator's Brochure (ICH E6 Section 6 & 7) 4.2 Essential Documents Checklist (ICH E6 Section 8) 4.3 Case Report Forms (CRFs) & Source Documentation
5 Chapter 5: Investigational Applications (IND & IDE)
5.1 Investigational New Drug (IND) Applications (21 CFR Part 312) 5.2 Investigational Device Exemptions (IDE) & Device Classification (21 CFR Part 812) 5.3 Expanded Access & Humanitarian Device Exemptions (HDE)
6 Chapter 6: Investigator & Sponsor Responsibilities
6.1 Investigator Responsibilities & Delegation (ICH E6 4.0 / 21 CFR 312.60) 6.2 Sponsor Roles, Responsibilities, and Quality Management (ICH E6 5.0) 6.3 Financial Agreements, Contracts, and Insurance
7 Chapter 7: Study Implementation & Clinical Operations
7.1 Subject Recruitment, Screening, and Enrolling Procedures 7.2 Investigational Product (IP) Receipt, Accountability, and Disposition 7.3 Protocol Compliance, Deviations, and Corrective Action Plans
8 Chapter 8: Safety Definitions & Reporting Workflows
8.1 Adverse Events, Serious Adverse Events, and SUSARs (ICH E2A) 8.2 Safety Reporting Timelines (Investigator-Sponsor-FDA-IRB) 8.3 Device-Related Safety Reporting & Unanticipated Adverse Device Effects (UADEs)
9 Chapter 9: Quality Assurance, Monitoring, and Auditing
9.1 Clinical Site Monitoring (Traditional vs. Risk-Based Monitoring) 9.2 Sponsor Audits vs. Regulatory Inspections 9.3 FDA BIMO Inspections, Form 483, and Warning Letters
10 Chapter 10: Study Closure & Final Disclosures
10.1 Close-Out Visits and Administrative Wrap-Up 10.2 Record Retention Regulations (FDA vs. ICH GCP) 10.3 Final Reporting & Registration (ClinicalTrials.gov / 42 CFR 11)
8.3 Device-Related Safety Reporting & Unanticipated Adverse Device Effects (UADEs)
Key Takeaways Explain This Topic AI
Unanticipated Adverse Device Effects (UADEs) are defined under 21 CFR 812.3(s) as any serious adverse effect on health or safety caused by or associated with a device that was not previously identified.
Investigators must report a UADE to the sponsor and the reviewing IRB as soon as possible, but no later than 10 working days after learning of the event.
Sponsors must evaluate UADEs and report findings to the FDA, reviewing IRBs, and investigators within 30 working days of receiving notice.
If a UADE presents an unreasonable risk to subjects, the sponsor must terminate the study within 5 working days of the determination and within 15 working days of notice.
Post-market device reporting under 21 CFR Part 803 requires user facilities to report device-related deaths within 10 work days and manufacturers to report deaths/serious injuries within 30 calendar days.
Last updated: July 2026
Safety monitoring for medical devices differs significantly from investigational drugs. Under the Investigational Device Exemption (IDE) regulations (21 CFR Part 812), the safety reporting nomenclature, definitions, and reporting timelines are distinct. Clinical research professionals must master these differences to avoid applying drug safety rules to device trials, which is a frequent source of compliance errors and exam confusion.
Understanding the IDE Safety Framework
In a medical device trial, the primary safety event requiring expedited reporting is the Unanticipated Adverse Device Effect (UADE). The UADE is the medical device equivalent of a drug SUSAR, but it has its own statutory definition and reporting rules.
Unanticipated Adverse Device Effect (UADE) Definition
According to 21 CFR 812.3(s), a UADE is defined as:
Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.
Key elements of the UADE definition:
Causality/Association: The event must be "caused by, or associated with" the device. This includes physical device malfunctions, clinical complications of the implantation procedure, or secondary physiological reactions to the device material.
Unanticipated Nature: The event must not have been previously identified in terms of:
Nature: The type of event (e.g., a device break that migrates to the heart, when only local breaks were expected).
Severity: The intensity of the event (e.g., severe inflammation requiring surgery, when only mild transient redness was expected).
Degree of Incidence: The frequency of the event (e.g., a known risk of thrombosis occurring at a rate of 5% in the trial, when the investigational plan estimated the incidence at less than 0.1%).
Device Safety Reporting Timelines
The reporting timelines for device trials are based on working days (Monday through Friday, excluding federal holidays), which differs from the calendar-day timelines used in drug trials.
Investigator-to-Sponsor and IRB Reporting
Under 21 CFR 812.150(a)(1), the investigator must submit a report of a UADE to both the sponsor and the reviewing IRB as soon as possible, but in no event later than 10 working days after the investigator first learns of the effect.
Dual Reporting: Unlike drug trials where the investigator reports only to the sponsor (and the sponsor handles regulatory distribution), device investigators have a statutory obligation to report the UADE directly to their local IRB and the sponsor within the same 10-working-day window.
Sponsor-to-FDA, IRBs, and Investigators Reporting
Under 21 CFR 812.150(b)(1), the sponsor must conduct an evaluation of the UADE and report the results of the evaluation to the FDA, all reviewing IRBs, and all participating investigators within 30 working days after the sponsor first receives notice of the effect.
Evaluation Obligation: The sponsor cannot simply pass the investigator's report along. They must conduct a formal evaluation of the device performance and clinical data, assess safety implications, and submit this evaluation within the 30-working-day window.
Unreasonable Risk and Study Termination (21 CFR 812.150(b)(2))
If the sponsor's evaluation of the UADE determines that the device presents an unreasonable risk to subjects, the sponsor must terminate the investigation (or the part of the investigation presenting the risk) as soon as possible.
Termination Timeline: Termination must occur no later than 5 working days after the sponsor makes the determination, and no later than 15 working days after the sponsor first receives notice of the UADE.
Resumption Requirements: If a study is terminated for safety reasons under this regulation, the sponsor cannot resume the investigation without FDA approval (and IRB approval for significant risk devices).
Safety Aspect Investigational Drug (IND - 21 CFR 312) Investigational Device (IDE - 21 CFR 812)
Primary Safety Term Suspected Unexpected Serious Adverse Reaction (SUSAR) Unanticipated Adverse Device Effect (UADE)
- Time Unit Calendar Days Working Days (Mon-Fri)
- Investigator to Sponsor Timeline Immediate / Within 24 hours Within 10 working days of awareness
- Investigator to IRB Timeline Promptly (defined by local IRB SOPs) Within 10 working days of awareness
Sponsor to FDA Timeline 7 calendar days (fatal/life-threatening); 15 calendar days (other SUSARs) Within 30 working days of receiving notice
- Sponsor to Other Investigators Within 15 calendar days Within 30 working days (included in UADE evaluation)
- Resumption After Safety Termination Permitted unless FDA issues clinical hold Requires explicit FDA approval
- Post-Market Device Safety: Medical Device Reporting (MDR)
Once a device is cleared or approved for marketing, safety reporting shifts from the IDE regulations to the Medical Device Reporting (MDR) regulation under 21 CFR Part 803. This is an administrative reporting system designed to monitor post-market device performance:
User Facilities (Hospitals): Must report device-related deaths to the FDA and the manufacturer within 10 work days , and device-related serious injuries to the manufacturer (or the FDA if the manufacturer is unknown) within 10 work days .
Manufacturers: Must report device-related deaths, serious injuries, or malfunctions that would be likely to cause death or serious injury if the malfunction were to recur, to the FDA within 30 calendar days (or 5 calendar days for events requiring remedial action to prevent systemic harm).